{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jain N"],"funding":["NCI NIH HHS","AbbVie"],"pagination":["2095-2103"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11827445"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["380(22)"],"pubmed_abstract":["<h4>Background</h4>Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations have indicated potential synergistic interaction of their combination.<h4>Methods</h4>We conducted an investigator-initiated phase 2 study of combined ibrutinib and venetoclax involving previously untreated high-risk and older patients with CLL. All patients had at least one of the following features: chromosome 17p deletion, mutated <i>TP53</i>, chromosome 11q deletion, unmutated <i>IGHV</i>, or an age of 65 years or older. Patients received ibrutinib monotherapy (420 mg once daily) for 3 cycles, followed by the addition of venetoclax (weekly dose escalation to "],"journal":["The New England journal of medicine"],"pubmed_title":["Ibrutinib and Venetoclax for First-Line Treatment of CLL."],"pmcid":["PMC11827445"],"funding_grant_id":["P30 CA016672"],"pubmed_authors":["Fowler N","Sasaki K","DiNardo C","Plunkett W","Keating M","Wierda W","Kadia T","Burger J","Kanagal-Shamanna R","Wang X","Takahashi K","Bose P","Patel K","Ohanian M","Jain N","Estrov Z","Yilmaz M","Wei C","Ayala A","Garg N","Ferrajoli A","Sondermann K","Jabbour E","Cruz N","Gandhi V","Konopleva M","Kantarjian H","Thompson P","Alvarado Y","Pemmaraju N","Jorgensen J","Borthakur G"],"additional_accession":[]},"is_claimable":false,"name":"Ibrutinib and Venetoclax for First-Line Treatment of CLL.","description":"<h4>Background</h4>Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations have indicated potential synergistic interaction of their combination.<h4>Methods</h4>We conducted an investigator-initiated phase 2 study of combined ibrutinib and venetoclax involving previously untreated high-risk and older patients with CLL. All patients had at least one of the following features: chromosome 17p deletion, mutated <i>TP53</i>, chromosome 11q deletion, unmutated <i>IGHV</i>, or an age of 65 years or older. Patients received ibrutinib monotherapy (420 mg once daily) for 3 cycles, followed by the addition of venetoclax (weekly dose escalation to ","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 May","modification":"2026-06-01T08:49:01.991Z","creation":"2025-04-07T11:28:29.649Z"},"accession":"S-EPMC11827445","cross_references":{"pubmed":["31141631"],"doi":["10.1056/nejmoa1900574","10.1056/NEJMoa1900574"]}}